Furthermore, it results in the upregulation of cyclin D1 and antiapoptotic protein B-cell lymphoma 2 (Bcl-2), thus raising the hypothesis of whether Bcl-2 inhibition could be a potential target in the treatment of t(11,14)(q13;q32) MM [7]. The gene discussed is BCL2; the disease is Miyoshi myopathy.